WellPoint Health Networks Inc.

Boehringer Ingelheim GMBH is hoping a BLA filed for its specific antidote to the novel anticoagulant Pradaxa will pave the way for accelerated approval based on Phase I data in healthy volunteers.

Boehringer Ingelheim GMBH is hoping a BLA filed for its specific antidote to the novel anticoagulant Pradaxa will pave the way for accelerated approval based on Phase I data in healthy volunteers.

Insurance plan formularies regulated under the Affordable Care Act should incorporate the recommendations of health plans’ pharmacy and therapeutics committees, payers and pharmaceutical firms agree i

Finally, some statistics about the impact of the Medicare Part D donut hole. The good news: drug manufacturers need not worry about most patients entering the coverage gap. The bad: a relatively large